Momenta Pharmaceuticals Культура компании

Mr. Craig A. Wheeler has been the Chief Executive Officer and President of Momenta Pharmaceuticals Inc. since September 12, 2006 and August 22, 2006, respectively. Mr. Wheeler has been an Executive Director at Momenta Pharmaceuticals Inc. since August 22, 2006. He led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX and once-daily COPAXONE. He has also overseen the growth into a diversified business, with a development pipeline of biosimilar biologics as well as novel therapeutics for oncology and autoimmune indications at Momenta Pharmaceuticals. He served as the Board Chairman, Treasurer and Secretary of Generic Pharmaceutical Association until February 22, 2016. Mr. Wheeler served as a Vice President of Chiron Corp. from August 2001 to June 2006. He served as the President of Chiron Biopharmaceuticals, a division of Chiron Corp. from August 2001 to June 2006. He was responsible for all aspects of the Biopharmaceuticals business unit, including commercial, research, development and manufacturing. During his tenure at Chiron, he led the restructuring of the business unit to refocus on oncology and infectious disease. Mr. Wheeler served as a Partner and served as a Senior Member of health care practice at The Boston Consulting Group and a key contributor to its practice in hospital strategy, disease management and pharmaceutical capabilities from August 1988 to August 2001. Mr. Wheeler served as a Senior Engineer in process development at Merck's MSDRL research unit. He served as the Leader of Scientist's Network at The Boston Consulting Group. In partnership with Rockefeller Foundation, he has joined Global Alliance for TB Drug Development. He served as a Financial Analyst for Hybritech. He has extensive professional experience in the biotechnology and healthcare industries. Mr. Wheeler served as the Chairman of Avanir Pharmaceuticals, Inc. from May 3, 2007 to January 13, 2015 and GPhA from 2014 to February 2016. He serves as a Director of Association for Accessible Medicines. He has been Director of Amicus Therapeutics, Inc. since June 10, 2016. Mr. Wheeler serves as a Director of California Healthcare Institute. He serves as a Member of the Chief Executive Officer Roundtable on Cancer, Inc. He also serves on the IBM Life Science Strategic Advisory Council and the Whitehead Institute for Biomedical Research's Board of Associates. He served as a Director of Association for Accessible Medicines (a/k/a Generic Pharmaceutical Association) until February 22, 2016. Mr. Wheeler served as a Director of Avanir Pharmaceuticals, Inc. from September 27, 2005 to January 13, 2015. In 2011 Mr. Wheeler was an E&Y Entrepreneur of the Year Regional Award winner. Mr. Wheeler holds BS and an MS Degree in Chemical Engineering from Cornell University and an MBA from the Wharton School of the University of Pennsylvania, where he majored in Marketing and Finance.

Mr. Bruce A. Leicher, J.D., has been Senior Vice President and General Counsel at Momenta Pharmaceuticals Inc. since July 2008. Mr. Leicher has been Secretary of Momenta Pharmaceuticals Inc. since September 2008. Mr. Leicher served as Senior Vice President, Secretary and General Counsel of Altus Pharmaceuticals Inc. from December 19, 2006 to July 18, 2008. Mr. Leicher has over 15 years experience in providing counsel in the life sciences industry. He has 25 years of legal experience, he has developed a specific expertise in implementing systems that facilitate accelerated product development and compliance with US and international regulatory requirements. He provided legal advice to Altus Pharmaceuticals Inc. on matters such as corporate governance and compliance, regulatory matters, business development, intellectual property and general corporate matters. He served as Secretary of Antigenics Inc. He served as Vice President and General Counsel of Antigenics Inc. from December 2005 to December 15, 2006. From January 2003 to November 2005, he served as Vice President, Chief Pharmaceutical Counsel and Compliance Officer of Millennium Pharmaceuticals. From January 2002 to December 2002, Mr. Leicher formed and co-chaired the Lifesciences Practice group at the law firm of Hill & Barlow after re-entering private practice on his representing and counseling biotechnologies companies on a variety of matters. He served as Vice President, General Counsel and Secretary of Curis Inc., since March 2000. He joined Ontogeny in January 2000 as Vice President and General Counsel. He joined Genetics Institute Inc. and served in various legal positions for ten years from 1990 to 1999 and for the last two years as Vice President, Law since 1996. He served as General Counsel of BBN Communications Corporation and in several other legal positions prior to that at its parent, Bolt, Beranek and Newman Inc. from 1984 to 1990. He served as a leader in the creation of the commercial infrastructure to launch Velcade(R) (bortezomib) - the first proteasome inhibitor approved by the US Food and Drug Administration - as a treatment for multiple myeloma at Millennium. He was associated with the law firms of Hale and Dorr and Butler & Binion in Boston and Washington, D.C., respectively. He has built and managed legal teams, trained clinical and R&D operations professionals to handle high-volume research and clinical contracts, participated in portfolio and strategic planning and managed significant product partnering and acquisition transactions. He received a Bachelor's degree in Psychology from the University of Rochester in New York and a Law degree from Georgetown University Law Center.

Mr. Scott M. Storer has been the Chief Financial Officer and Senior Vice President at Momenta Pharmaceuticals, Inc. since November 28, 2016 and its Treasurer since June 6, 2017. Mr. Storer was Senior Vice President of Finance at Baxalta, Inc. He joined Baxter in 1997 and served as its Vice President of BioScience Finance.

Dr. Ganesh Venkataraman Kaundinya, Ph.D. is a Co-Founder of Momenta Pharmaceuticals Inc. and has been Chief Scientific Officer since September 2007. Dr. Kaundinya has been Senior Vice President of Momenta Pharmaceuticals, Inc. since June 6, 2017 and has been its Chief Operating Officer since September 25, 2017. He served as Senior Vice President of Research at Momenta Pharmaceuticals, Inc. since April 2005 until June 6, 2017. Dr. Venkataraman served as Vice President of Technology at Momenta Pharmaceuticals Inc. from August 2002 to April 2005. He served as the Director of Bioinformatics for the Consortium for Functional Glycomics from August 2000 to January 2003 to study the role of complex sugars in biology. Dr. Venkataraman served as a Research Faculty Member of the Harvard of M.I.T. division of Health and Sciences and Technology from March 1995 to July 2000, where he investigated the biochemistry and biophysics of carbohydrates and research in the area of analytical techniques for complex carbohydrates. He has been a Member of Scientific Advisory Board at Siamab Therapeutics, Inc. (formerly Sialix, Inc.) since December 4, 2012. He received his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Michelle Robertson serves as the CFO & Treasurer of Momenta Pharmaceuticals. Michelle started at Momenta Pharmaceuticals in Oct of 2018. Michelle currently resides in the Greater Boston Area.

Ganesh Kaundinya serves as the Chief Operations Officer and CSO of Momenta Pharmaceuticals. Ganesh started at Momenta Pharmaceuticals in Sep of 2017. Ganesh currently resides in the Greater Boston Area.

Jim Anderson serves as the Senior Vice President Pharmaceutical Sciences of Momenta Pharmaceuticals. Jim started at Momenta Pharmaceuticals in May of 2016. Jim currently resides in the Greater Boston Area.

Brian York serves as the Vice President Clinical Operations of Momenta Pharmaceuticals. Brian started at Momenta Pharmaceuticals in Aug of 2018. Brian currently resides in the Greater Boston Area.

Bilal Arif serves as the Vice President Technical Operations of Momenta Pharmaceuticals. Bilal started at Momenta Pharmaceuticals in Mar of 2017. Bilal currently resides in the Greater Boston Area.

Bill Desmarais serves as the Vice President, Business Development of Momenta Pharmaceuticals. Bill started at Momenta Pharmaceuticals in Sep of 2017. Bill currently resides in the Indianapolis, Indiana Area.